Wall Street analysts forecast that Agios Pharmaceuticals Inc (NASDAQ:AGIO) will announce ($1.60) earnings per share for the current quarter, Zacks reports. Two analysts have issued estimates for Agios Pharmaceuticals’ earnings. The highest EPS estimate is ($1.54) and the lowest is ($1.65). Agios Pharmaceuticals reported earnings of ($1.56) per share during the same quarter last year, which would suggest a negative year-over-year growth rate of 2.6%. The firm is expected to announce its next quarterly earnings report on Thursday, May 3rd.
On average, analysts expect that Agios Pharmaceuticals will report full year earnings of ($6.15) per share for the current fiscal year, with EPS estimates ranging from ($6.51) to ($5.60). For the next fiscal year, analysts anticipate that the company will report earnings of ($4.42) per share, with EPS estimates ranging from ($6.00) to ($0.01). Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research analysts that follow Agios Pharmaceuticals.
Agios Pharmaceuticals (NASDAQ:AGIO) last announced its earnings results on Wednesday, February 14th. The biopharmaceutical company reported ($1.81) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.65) by ($0.16). Agios Pharmaceuticals had a negative return on equity of 76.67% and a negative net margin of 731.60%. The company had revenue of $9.80 million during the quarter, compared to analysts’ expectations of $12.65 million. During the same quarter last year, the firm posted ($1.34) earnings per share. The firm’s revenue was down 56.7% on a year-over-year basis.
Several research analysts recently issued reports on the stock. UBS Group lowered shares of Agios Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research report on Wednesday, February 14th. Needham & Company LLC upped their target price on shares of Agios Pharmaceuticals from $72.00 to $86.00 and gave the stock a “buy” rating in a research report on Thursday, February 15th. SunTrust Banks reiterated a “buy” rating and issued a $101.00 target price (up from $80.00) on shares of Agios Pharmaceuticals in a research report on Thursday, February 15th. Oppenheimer set a $83.00 target price on shares of Agios Pharmaceuticals and gave the stock a “buy” rating in a research report on Tuesday, December 26th. Finally, Zacks Investment Research upgraded shares of Agios Pharmaceuticals from a “hold” rating to a “buy” rating and set a $68.00 target price for the company in a research report on Tuesday, January 9th. Four equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. Agios Pharmaceuticals has an average rating of “Buy” and a consensus target price of $85.50.
Agios Pharmaceuticals (AGIO) opened at $77.70 on Tuesday. Agios Pharmaceuticals has a 1 year low of $45.11 and a 1 year high of $82.96. The stock has a market cap of $4,450.00, a price-to-earnings ratio of -11.53 and a beta of 2.12.
In other Agios Pharmaceuticals news, insider Steven L. Hoerter sold 25,000 shares of the company’s stock in a transaction dated Tuesday, January 23rd. The shares were sold at an average price of $74.83, for a total transaction of $1,870,750.00. Following the completion of the sale, the insider now directly owns 25,000 shares in the company, valued at $1,870,750. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Scott Biller sold 2,146 shares of the company’s stock in a transaction dated Friday, December 1st. The shares were sold at an average price of $60.79, for a total transaction of $130,455.34. Following the sale, the insider now owns 8,410 shares of the company’s stock, valued at $511,243.90. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 183,114 shares of company stock valued at $13,866,025. Company insiders own 5.43% of the company’s stock.
Hedge funds and other institutional investors have recently bought and sold shares of the business. Alliancebernstein L.P. boosted its holdings in shares of Agios Pharmaceuticals by 16.3% during the second quarter. Alliancebernstein L.P. now owns 21,742 shares of the biopharmaceutical company’s stock worth $1,119,000 after purchasing an additional 3,050 shares during the period. Ameriprise Financial Inc. boosted its holdings in shares of Agios Pharmaceuticals by 21.9% during the second quarter. Ameriprise Financial Inc. now owns 49,994 shares of the biopharmaceutical company’s stock worth $2,572,000 after purchasing an additional 8,965 shares during the period. Northern Trust Corp boosted its holdings in shares of Agios Pharmaceuticals by 31.3% during the second quarter. Northern Trust Corp now owns 232,802 shares of the biopharmaceutical company’s stock worth $11,977,000 after purchasing an additional 55,560 shares during the period. California Public Employees Retirement System boosted its holdings in shares of Agios Pharmaceuticals by 2.3% during the second quarter. California Public Employees Retirement System now owns 34,900 shares of the biopharmaceutical company’s stock worth $1,796,000 after purchasing an additional 800 shares during the period. Finally, Ark Investment Management LLC boosted its holdings in shares of Agios Pharmaceuticals by 66.2% during the second quarter. Ark Investment Management LLC now owns 10,713 shares of the biopharmaceutical company’s stock worth $551,000 after purchasing an additional 4,267 shares during the period. Institutional investors and hedge funds own 84.04% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Brokerages Anticipate Agios Pharmaceuticals Inc (AGIO) Will Post Earnings of -$1.60 Per Share” was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this news story on another website, it was illegally stolen and reposted in violation of US & international trademark & copyright law. The correct version of this news story can be accessed at https://www.dispatchtribunal.com/2018/02/20/brokerages-anticipate-agios-pharmaceuticals-inc-agio-will-post-earnings-of-1-60-per-share.html.
About Agios Pharmaceuticals
Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.
Get a free copy of the Zacks research report on Agios Pharmaceuticals (AGIO)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.